Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12-week randomized double-blind placebo-controlled phase 4 study of fesoterodine doses in overactive bladder
2010-024181-22Phase 4Completed
- Sponsor
- Pfizer
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fesoterodine in overactive bladder (OAB) (3 arms), sponsored by Pfizer. Primary endpoint: Change in mean number of urgency urinary incontinence episodes per 24 hours at Week 12. Started Mar 2011; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on 2010-024181-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024181-22.